Hormone Receptor-Positive

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,

By MedXY 05/18/2026

A national database study found that neoadjuvant chemotherapy was linked to worse overall survival than upfront surgery in node-positive hormone receptor-positive, HER2-negative breast cancer, except in patients who achieved nodal complete response.

Clinical Updates news Oncology Specialties

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

By MedXY 09/25/2025

Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg as the starting dose with dose reductions for adverse events.

Clinical Updates news Oncology

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY 09/08/2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemotherapy.